Photodynamic therapy in oncology
M Triesscheijn, P Baas, JHM Schellens… - The oncologist, 2006 - academic.oup.com
… Jan HM Schellens , Jan HM Schellens … Martijn Triesscheijn, Paul Baas, Jan HM Schellens,
Fiona A. Stewart, Photodynamic Therapy in Oncology, The Oncologist, Volume 11, Issue 9, …
Fiona A. Stewart, Photodynamic Therapy in Oncology, The Oncologist, Volume 11, Issue 9, …
An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons
…, I Meijerman, JH Beijnen, JHM Schellens - Toxicology and applied …, 2003 - Elsevier
The liver is the predominant organ in which biotransformation of foreign compounds takes
place, although other organs may also be involved in drug biotransformation. Ideally, an in …
place, although other organs may also be involved in drug biotransformation. Ideally, an in …
Clinical pharmacokinetics of therapeutic monoclonal antibodies
RJ Keizer, ADR Huitema, JHM Schellens… - Clinical …, 2010 - Springer
Monoclonal antibodies (mAbs) have been used in the treatment of various diseases for over
20 years and combine high specificity with generally low toxicity. Their pharmacokinetic …
20 years and combine high specificity with generally low toxicity. Their pharmacokinetic …
[HTML][HTML] Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
…, J Carmichael, SB Kaye, JHM Schellens… - … England Journal of …, 2009 - Mass Medical Soc
Background The inhibition of poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP)
is a potential synthetic lethal therapeutic strategy for the treatment of cancers with specific …
is a potential synthetic lethal therapeutic strategy for the treatment of cancers with specific …
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues
…, MJ van de Vijver, RJ Scheper, JHM Schellens - Cancer research, 2001 - AACR
High expression of the Breast Cancer Resistance Protein (BCRP) gene has been shown to
be involved in resistance to chemotherapeutic drugs. Knowledge of the localization of BCRP …
be involved in resistance to chemotherapeutic drugs. Knowledge of the localization of BCRP …
[HTML][HTML] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
…, E Elez, TW Kim, JHM Schellens… - … England Journal of …, 2019 - Mass Medical Soc
Background Patients with metastatic colorectal cancer with the BRAF V600E mutation have
a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy…
a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy…
[PDF][PDF] Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
…, J Stone, J Carmichael, JHM Schellens… - Journal of clinical …, 2010 - researchgate.net
Purpose Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy
using poly (ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers …
using poly (ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers …
A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent
…, D Pluim, JH Beijnen, JHM Schellens - Clinical Cancer …, 2004 - AACR
Purpose: NAMI-A {H 2 Im[trans-RuCl 4 (DMSO)HIm] or imidazolium-trans-DMSO-imidazole-tetrachlororuthenate}
is a novel ruthenium-containing compound that has demonstrated …
is a novel ruthenium-containing compound that has demonstrated …
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan
…, JH Beijnen, JHM Schellens… - Journal of the …, 2000 - academic.oup.com
Background and Methods: Breast cancer resistance protein (BCRP/MXR/ABCP) is a
multidrug-resistance protein that is a member of the adenosine triphosphate-binding cassette family …
multidrug-resistance protein that is a member of the adenosine triphosphate-binding cassette family …
Potent and Specific Inhibition of the Breast Cancer Resistance Protein Multidrug Transporter in Vitro and in Mouse Intestine by a Novel Analogue of Fumitremorgin C
…, O Van Tellingen, G Reid, JHM Schellens… - Molecular cancer …, 2002 - AACR
Inhibitors of the breast cancer resistance protein (BCRP/ABCG2) multidrug transporter are of
interest as chemosensitizers for clinical drug resistance, for improving the pharmacokinetics …
interest as chemosensitizers for clinical drug resistance, for improving the pharmacokinetics …